Picture loading failed.

Anti-CA125 therapeutic antibody (Pre-made Abagovomab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is hoped that the body's immune system may be able to combat any remaining individual tumour cells and thus prevent recurrence of the disease.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-001-1mg 1mg 3090
GMP-Bios-ab-001-10mg 10mg 21890
GMP-Bios-ab-001-100mg 100mg 148000
GMP-Bios-ab-001-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CA125 therapeutic antibody (Pre-made Abagovomab biosimilar,Whole mAb)
INN Name Abagovomab
TargetCA125
FormatWhole mAb
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2006
Year Recommended2007
CompaniesMenarini
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedOvarian cancer;Pancreatic cancer
Development Techna